Abartis Pharma is seeking to rapidly expand its product portfolio in the European Union. Our business development activities are focused on prescription branded and generic products currently approved and commercialized and falling outside the license holder’s business focus. Abartis Pharma consider in-licensing, acquisition, co-promotion, revenue-sharing, and other partnering opportunities.
Therapeutic categories of primary interest for proprietary products include psychiatry, neurology, pain management, cardiology, infectious disease, ophtalmology, urology, dietary supplements and medical devices although we will consider other opportunities outside of these areas.